Evidence map›Paper›PMID 42889250›Full record

ArticleJournal of the Endocrine Society2026

Health utility, work productivity, and total economic burden of polycystic ovary syndrome.

Mina Amiri, Yucheng Huang, Linda Thai, Sasha Ottey, William Patterson, Olivia R Delau, Surabhi Yadav, Kendall Soucie, Ty Partridge, Richard P Buyalos and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the Endocrine Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mina AmiriMaternal, Fetal, & Neonatal Research Center, Family Health Institute,Tehran University of Medical Sciences (TUMS), Tehran 1419733141, Iran.ORCID https://orcid.org/0000-0002-1126-9297
Yucheng HuangPCOS Challenge: The National Polycystic Ovary Syndrome Association, Atlanta, GA 30308, USA.
Linda ThaiPCOS Challenge: The National Polycystic Ovary Syndrome Association, Atlanta, GA 30308, USA.
Sasha OtteyPCOS Challenge: The National Polycystic Ovary Syndrome Association, Atlanta, GA 30308, USA.
William PattersonPCOS Challenge: The National Polycystic Ovary Syndrome Association, Atlanta, GA 30308, USA.
Olivia R DelauPCOS Challenge: The National Polycystic Ovary Syndrome Association, Atlanta, GA 30308, USA.
Surabhi YadavPCOS Challenge: The National Polycystic Ovary Syndrome Association, Atlanta, GA 30308, USA.
Kendall SoucieDepartment of Psychology, University of Windsor, Windsor, ON N9B 3P4, Canada.
Ty PartridgeDepartment of Psychology, Wayne State University, Detroit, MI 48202, USA.
Richard P BuyalosFoundation for Research and Education Excellence, Vestavia, AL 35243, USA.
Ricardo AzzizFoundation for Research and Education Excellence, Vestavia, AL 35243, USA.ORCID https://orcid.org/0000-0002-3917-0483

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Polycystic ovary syndrome (PCOS), also known as polyendocrine metabolic ovarian syndrome (PMOS), impairs health-related quality of life (QoL) and daily functioning. While estimates of medical-related costs have been made, this study aimed to estimate indirect (work productivity-related) and intangible (QoL-related) economic costs. Methods: In a cross-sectional US registry (PCOS/PMOS = 433, controls = 252), we measured willingness to pay, health utility using the EuroQol five-dimension five-level (EQ-5D-5L) and the Short Form 6-Dimensions (SF-6D) tools, and work productivity with Work Productivity and Activity Impairment: General Health. Adjusted regression estimated utility differences were converted to quality-adjusted life year (QALY) loss. XGBoost classification with Shapley Additive exPlanations feature importance identified key discriminating domains. Results: PCOS/PMOS had lower health utility compared to controls (EQ-5D-5L, 0.72 vs 0.88; SF-6D, 0.67 vs 0.72; Conclusion: PCOS/PMOS is associated with lower utility, significant QALY losses, and work productivity impairment. Considering prior estimates of medical-related costs, the total annual US Societal burden ranges from $133 to $169 billion, predominantly from indirect and intangible costs, underscoring the profound functional and economic impact of the disorder.

Indexed as

cost of illnesshealth utilitypolycystic ovary syndromepolyendocrine metabolic ovarian syndromequality-adjusted life yearswork productivity

Identifiers

PMID42889250
PMCPMC13669623

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.